Study of HSK50042 for Idiopathic Pulmonary Fibrosis
Part of Lungs & breathing clinical trials.
This trial tests a new oral medication, HSK50042, for people with Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the drug can help slow lung function decline, and is looking for patients who meet specific lung function criteria and are either not currently on anti-fibrotic therapy or on a stable dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of Idiopathic Pulmonary Fibrosis (IPF) based on a chest CT scan or lung biopsy.
- Your lung function must meet certain levels: FVC (breathing out capacity) at 45% or more of normal, and DLCO (gas exchange) between 25% and 90% of normal.
- You should either not be on IPF medications (nintedanib or pirfenidone) for at least 8 weeks, or be taking a stable dose of one of these for at least 12 weeks.
- You cannot have a history of fainting or conditions that increase fainting risk, or have had a sudden IPF worsening in the last 3 months.
- You must not have other significant lung problems (like asthma or COPD) or uncontrolled high/low blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks the long-term safety of HSK44459 for people with IPF who have already taken it in a previous study. It is only for those who finished the prior treatment without major issues and may benefit from continuing.
This trial tests a new tablet, HEC585, for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug can help improve lung function and slow the disease. Participants must have a confirmed IPF diagnosis and meet specific breathing test results.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
This study tests a new medication called AK3280 for people with idiopathic pulmonary fibrosis (IPF), a lung condition. The goal is to see if AK3280 can help improve lung function. To join, you must have a confirmed IPF diagnosis and meet certain health criteria.
This trial tests a liquid version of the medication nintedanib (AP02) to see if it is safe and works well for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and have not taken nintedanib or pirfenidone recently, you may be able to join.
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
Hear when a new Idiopathic Pulmonary Fibrosis (IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.